These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 36636712

  • 1. The Predictive Value of the CHA2DS2-VASc Score for In-Stent Restenosis Among Patients with Drug-Eluting Stents Implantation.
    Zhao J, Hou L, Zhu N, Huang R, Su K, Lei Y, Li Y.
    Int J Gen Med; 2023; 16():69-76. PubMed ID: 36636712
    [Abstract] [Full Text] [Related]

  • 2. CHA2DS2-Vasc score and CHA2DS2-Vasc-HS score are poor predictors of in-stent restenosis among patients with coronary drug-eluting stents.
    Zhao SG, Xu JJ, Tao ZH, Jin L, Liu Q, Zheng WY, Jiang LQ, Wang NF.
    J Int Med Res; 2019 Jun; 47(6):2533-2544. PubMed ID: 31039653
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of the Predictive Value of CHA2DS2-VASc Score for In-Stent Restenosis.
    Yilmaz S, Akboga MK, Aras D, Topaloglu S.
    Angiology; 2018 Jan; 69(1):38-42. PubMed ID: 28345395
    [Abstract] [Full Text] [Related]

  • 4. Usefulness of the CHA2DS2-VASc Score in Predicting In-Stent Restenosis Among Patients Undergoing Revascularization With Bare-Metal Stents.
    Kurtul A.
    Clin Appl Thromb Hemost; 2018 May; 24(4):589-595. PubMed ID: 28675046
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Risk investigation of in-stent restenosis after initial implantation of intracoronary drug-eluting stent in patients with coronary heart disease.
    Xi H, Liu J, Xu T, Li Z, Mou X, Jin Y, Xia S.
    Front Cardiovasc Med; 2023 May; 10():1117915. PubMed ID: 36970340
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Using XGBoost for Predicting In-Stent Restenosis Post-DES Implantation: Role of Lymphocyte-to-Monocyte Ratio and Residual Cholesterol.
    Hou L, Su K, He T, Zhao J, Li Y.
    Int J Gen Med; 2024 May; 17():3443-3452. PubMed ID: 39139709
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Investigation Into the Risk Factors Related to In-stent Restenosis in Elderly Patients With Coronary Heart Disease and Type 2 Diabetes Within 2 Years After the First Drug-Eluting Stent Implantation.
    Yi M, Tang WH, Xu S, Ke X, Liu Q.
    Front Cardiovasc Med; 2022 May; 9():837330. PubMed ID: 35669469
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pre-stroke CHADS2 and CHA2DS2-VASc scores are useful in stratifying three-month outcomes in patients with and without atrial fibrillation.
    Tu HT, Campbell BC, Meretoja A, Churilov L, Lees KR, Donnan GA, Davis SM.
    Cerebrovasc Dis; 2013 May; 36(4):273-80. PubMed ID: 24135809
    [Abstract] [Full Text] [Related]

  • 20. Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention.
    Takasawa Y, Iijima R, Shiba M, Nakamura M, Sugi K.
    J Cardiol; 2010 May; 55(3):391-6. PubMed ID: 20350511
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.